Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radequinil in mild to moderate Alzheimer's Disease
NCT00359944Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of radequinil in Alzheimer's disease (AD) (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Alzheimer's Disease Assessment Scale - Cognition Subscale at 16 weeks. Started Feb 2006; status: completed.
02
Drugs
radequinil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00359944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359944.